Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Quantitative and qualitative methods for measuring chromosomal instability in tumor cells.

Cancer genetics·2025
Same author

Hydroethanolic Soy Extract Rich in Isoflavones Protects Dystrophic Mutant Mice From Oxidative Stress and Inflammation via the ROS/NF-κB Feedback Pathway.

BioFactors (Oxford, England)·2025
Same author

HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells.

Investigational new drugs·2025
Same author

Treatment With Full-Spectrum Cannabidiol Oil Improved the Pathological Findings of Dystrophic Mutant Mice.

Muscle & nerve·2025
Same author

WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells.

Cancer chemotherapy and pharmacology·2025

相关实验视频

Updated: Jun 3, 2025

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.5K

HDAC6:瘤的进展和超越

João Marcos Oliveira-Silva1,2, Leilane Sales de Oliveira1,2, João Vitor Marangoni Tagliéri1

  • 1Human Genetics Laboratory, Institute of Natural Sciences, Federal University of Alfenas (UNIFAL-MG), Alfenas, 37130-001, MG, Brazil.

Current cancer drug targets
|January 9, 2025
PubMed
概括

基因组脱酸酶6 (HDAC6) 是一个有前途的癌症标,因为它的细胞质作用和非基因组标. HDAC6抑制剂在治疗各种癌症方面显示出潜力,并在临床试验中取得进展.

关键词:
在 HDAC6 中.选择性抑制剂.选择性抑制剂.固体瘤是一种固体瘤.治疗目标是治疗的目标.

更多相关视频

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.7K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K

相关实验视频

Last Updated: Jun 3, 2025

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.5K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.7K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K

科学领域:

  • 生物化学 生物化学
  • 分子生物学分子生物学
  • 在瘤学瘤学.

背景情况:

  • 基因组脱酶6 (HDAC6) 在HDAC中是独一无二的,主要位于细胞质中.
  • 它拥有两个催化域和一个独特的泛素结合域.
  • HDAC6脱乙化非希斯基质,如α-tubulin,HSP90和cortactin. 这类基质是非希斯基质.

研究的目的:

  • 审查HDAC6.6的结构特征.
  • 阐明HDAC6在瘤进展中的生物学功能.
  • 讨论HDAC6抑制剂在癌症治疗中的治疗潜力.

主要方法:

  • 审查关于HDAC6结构和功能的现有文献.
  • 对HDAC6在关键癌症特征中的作用的分析.
  • 来自HDAC6抑制剂的临床前和临床试验数据的汇编.

主要成果:

  • HDAC6影响瘤入侵,转移,血管生成,药物耐药性,干性和免疫逃避.
  • 选择性HDAC6抑制剂正在针对固体和血液瘤进行研究.
  • 几种HDAC6抑制剂已经进入临床试验,初步结果是积极的.

结论:

  • 在瘤学中,HDAC6是重要的治疗点.
  • 准HDAC6为癌症治疗提供了一个有希望的策略.
  • 目前正在进行的临床试验正在评估HDAC6抑制剂的疗效.